Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: May 14, 2024
Context: This filing incorporates by reference a press release (Exhibit 99.1) dated May 14, 2024. The document serves as a formal notification to the SEC regarding material events disclosed in the referenced press release. The filing is signed by Hervé Brailly, Chairman of the Executive Board and Chief Executive Officer.
Key Financial Metrics
The provided Form 6-K text does not contain specific financial data. It acts as a cover document incorporating a press release by reference. Consequently, the following metrics are not present in the source text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Note: The filing text explicitly states that information contained in or accessed through website references is not part of this report.
Material Changes
The filing text does not detail specific material changes, operational updates, or comparative period analysis. The substantive content regarding material events is located in the incorporated Exhibit 99.1 (Press Release), which is not included in the provided input text.
Guidance, Outlook, and Risks
No guidance, outlook, management commentary, risks, contingencies, or unusual items are described within the body of this Form 6-K. The document focuses solely on the administrative incorporation of the press release into the company's registration statements (Form F-3 and Form S-8).
Investor Verification Checklist
- Review the full text of Exhibit 99.1 (Press Release dated May 14, 2024) to understand the specific event triggering this filing.
- Verify the impact of the disclosed event on the company's pipeline or operations, as the Form 6-K itself contains no operational details.
- Check the company's most recent Form 20-F or quarterly reports for the latest available financial metrics, as this filing does not provide them.
- Confirm the status of the registration statements (Form F-3 No. 333-276164 and Form S-8 No. 333-257834) referenced for incorporation.